

1 Evaluation of the CD4⁺ T cell response to SARS-CoV-2 infection and cross re-
2 activity to beta variant in children of all ages

3 Working Title: CD4⁺ T cell responses in children after COVID-19

4 Kevin Paul, M.D.^{1,2}; Freya Sibbertsen¹; Daniela Weiskopf, Ph.D.⁹; Marc Lütgehetmann, M.D.³;
5 Madalena Barroso, Ph.D.¹; Marta K. Danecka, Ph.D.¹; Laura Glau⁴; Laura Hecher, M.D.²;
6 Katharina Hermann, M.D.²; Aloisa Kohl, M.D.²; Jun Oh, M.D.¹; Julian Schulze zur Wiesch,
7 M.D.⁵; Alessandro Sette, Ph.D.^{9,10}, Eva Tolosa, Ph.D.⁴; Eik Vettorazzi⁶; Mathias Woidy,
8 M.D.^{1,2}; Antonia Zapf, Ph.D.⁶; Dimitra E. Zazara, M.D., Ph.D.^{2,7}; Thomas S. Mir, M.D.⁸; Ania C.
9 Muntau, M.D.²; Søren W. Gersting, M.D.¹; Gábor A. Dunay, M.D., Ph.D.^{1,2}

10

11 Author Affiliations

12 University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251 Hamburg, Germany

13 ¹University Children's Research, UCR@Kinder-UKE

14 ²Department of Pediatrics, Kinder-UKE

15 ³Institute of Medical Microbiology, Virology and Hygiene

16 ⁴Institute for Immunology

17 ⁵I. Department of Medicine, Division of Infectious Diseases

18 ⁶Institute of Medical Biometry and Epidemiology

19 ⁷Division for Experimental Feto-Maternal Medicine, Department of Obstetrics and Prenatal
20 Medicine

21 ⁸Department of Pediatric Cardiology

22 ⁹Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla,
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 CA 92037, USA

24 ¹⁰Department of Medicine, Division of Infectious Diseases and Global Public Health, University
25 of California, San Diego (UCSD), La Jolla, CA 92037, USA

26

27 Correspondence to Gábor A. Dunay, University Children's Research, UCR@Kinder-UKE, Uni-
28 versity

29 Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251 Hamburg, Germany, +49 40 7410
30 18775,

31 g.dunay@uke.de

32 **Abstract**

33 SARS-CoV-2 is still a major burden for global health despite effective vaccines. With the re-
34 duction of social distancing measures, infection rates are increasing in children, while data on
35 the pediatric immune response to SARS-CoV-2 infection is still lacking. Although the typical
36 disease course in children has been mild, emerging variants may present new challenges in this
37 age group.

38 Peripheral blood mononuclear cells (PBMC) from 51 convalescent children, 24 seronegative
39 siblings from early 2020, and 51 unexposed controls were stimulated with SARS-CoV-2-de-
40 rived peptide MegaPools from the ancestral and beta variants. Flow cytometric determination
41 of activation-induced markers and secreted cytokines were used to quantify the CD4⁺ T cell
42 response.

43 The average time after infection was over 80 days. CD4⁺ T cell responses were detected in 61%
44 of convalescent children and were markedly reduced in preschool children. Cross-reactive T
45 cells for the SARS-CoV-2 beta variant were identified in 45% of cases after infection with an
46 ancestral SARS-CoV-2 variant. The CD4⁺ T cell response was accompanied most predomi-
47 nantly by IFN- γ and Granzyme B secretion.

48 An antiviral CD4⁺ T cell response was present in children after ancestral SARS-CoV-2 infec-
49 tion, which was reduced in the youngest age group. We detected significant cross-reactivity of
50 CD4⁺ T cell responses to the more recently evolved immune-escaping beta variant. Our find-
51 ings have epidemiologic relevance for children regarding novel viral variants of concern and
52 vaccination efforts.

53

54 **Introduction**

55 The SARS-CoV-2 virus appeared in 2019 ¹ causing a pandemic which, despite effective vac-
56 cination, is still a major threat to global health². Children in particular are now facing increasing
57 infection rates due to a reduction of social distancing measures while vaccination of younger
58 age groups has just begun or is not yet available. So far, the disease course in the younger
59 population appears to be mild ^{3,4}, however emerging variants may present new challenges. With
60 the current emerging omicron variant hospitalization rates of young children, in particular, ap-
61 pear to be on the rise ⁵. Information on the pediatric immune response after infection or vac-
62 cination is of great importance for planning protective strategies in the future. However, data
63 on T cell-mediated immunity in children is still lacking. The identification of antigen-specific
64 T cells via stimulation of patient PBMC with viral peptide pools followed by detection of reac-
65 tive T cells through activation-induced markers allows the identification and simultaneous phe-
66 notyping of these cells using limited available patient material ⁶ and has been broadly used to
67 identify SARS-CoV-2 reactive T cells in adults ⁷⁻¹⁴, and children ^{15,16}. The COVID-19 Child
68 Health Investigation of Latent Disease (C19.CHILD) Hamburg Study recruited children from
69 all age groups after the spring 2020 wave of SARS-CoV-2 infections in Hamburg, Germany.
70 Here, PBMC from over fifty SARS-CoV-2 convalescent children, their exposed siblings and
71 unexposed age-matched controls from the C19.CHILD cohort were stimulated with peptide
72 MegaPools (MP) spanning the entire SARS-CoV-2 Spike Glycoprotein of the Wuhan-Hu-1
73 strain and beta variant as well as predicted peptides representing the remaining entire SARS-
74 CoV-2 Wuhan-Hu-1 strain proteome ¹⁷ to detect and characterize virus-specific CD4+ T cell
75 responses.

76

77 **Methods**

78 Study cohort and ethics

79 SARS-CoV-2 convalescent children, exposed seronegative siblings as well as unexposed con-
80 trols were identified from the COVID-19 Child Health Investigation of Latent Disease
81 (C19.CHILD) Hamburg Study cohort, registered at clinicaltrials.gov (NCT04534608). Briefly,
82 6113 children (<18 years) who presented voluntarily or were recruited while receiving care in
83 one of the five pediatric hospitals of Hamburg, Germany, were invited for a screening for an
84 acute or recent SARS-CoV-2 infection via PCR and serum antibody testing.
85 Patients who tested positive in the PCR and/or the antibody screening were invited with all
86 household members for a follow-up appointment, where detailed history was obtained and PCR
87 and serologic SARS-CoV-2 testing were repeated. PBMC samples were obtained from all fam-
88 ily members under 18 years. Pediatric unexposed and healthy volunteers, with no known SARS-
89 CoV-2 contact, were welcomed to enrol through the C19.CHILD Study Clinic.
90 Recruiting was conducted from May 11th until June 30th 2020 after the first infection wave,
91 during and after the first lockdown in Germany. Parents or legal guardians provided written
92 informed consent in all cases. From children over 7 years, consent in writing was obtained
93 whenever possible but also consent in spoken word was accepted. The study was approved by
94 the local ethical committee of Hamburg (reference number: PV7336).

95 Serum antibody measurements

96 For screening purposes, serum samples were tested for SARS-CoV-2 specific antibodies di-
97 rected against the viral nucleocapsid (IgA/IgM/IgG) using Elecsys® Anti-SARS-CoV-2 Ig as-
98 say (Roche) on the cobas e411 system (Roche). Additionally, serum samples were tested for
99 SARS-CoV-2 specific antibodies against the S1 and S2 subunits of the viral Spike protein using
100 LIAISON® SARS-CoV-2 IgG serology test (DiaSorin).
101 To evaluate serostatus for “common cold” coronaviruses (HCoV) and to further confirm SARS-
102 CoV-2 serostatus, serum antibodies (IgG) against the viral nucleocapsid of HCoV strains 229E,
103 NL63, OC43, HKU1 and SARS-CoV-2 anti - S1 subunit, anti - receptor binding domain as well

104 as anti - nucleocapsid were measured by using the recomLine SARS-CoV-2 IgG® assay
105 (Mikrogen).

106 Antibody screening was performed IVD conform according to the manufacturer's instructions.
107 Since patient recruiting was performed in a low prevalence setting, (<5 %), we used an orthog-
108 onal testing algorithm. Therefore, samples were considered as SARS-CoV-2 positive if all three
109 tests were positive, negative in three tests was considered as SARS-CoV-2 negative. Partici-
110 pants with discordant results were excluded from later analysis. Unexposed controls were re-
111 quired to report no known SARS-CoV-2 exposure and to be negative in the SARS-CoV-2 PCR
112 test and in the three antibody tests.

113 Sample acquisition / processing

114 Pediatric blood samples (2-10 ml) were collected in EDTA and processed within 24 hours.
115 PBMC were isolated by gradient centrifugation using SepMate tubes® and Lymphoprep®
116 (StemCell) according to the manufacturer's instructions. PBMC were cryopreserved in freezing
117 medium containing 50% FBS (Capricorn), 30% RPMI (Gibco) and 20% DMSO (AppliChem)
118 and stored in liquid nitrogen until further analysis.

119 For analysis, frozen aliquots of PBMC were incubated for one minute in a 37°C water bath, and
120 subsequently thawed in prewarmed RPMI by gentle pipetting.

121 PBMC peptide stimulation

122 Peptide stimulation was conducted using previously described ^{14,17} peptide MegaPools opti-
123 mized for stimulation of CD4+ T cells spanning the entire SARS-CoV-2 spike glycoprotein
124 (Spike-OS_MP) as well as predicted peptides representing the remaining entire SARS-CoV-2
125 proteome (R_MP) of the first described original strain (Wuhan-Hu-1). Additionally, a peptide
126 pool of overlapping 15-mer by 10 amino acids covering the entire SARS-CoV-2 beta variant
127 spike glycoprotein (Spike-BV_MP) was used.

128 Thawed PBMC were incubated in 5ml RPMI + human serum (Pan Biotech) 5% + Benzonase
129 (Sigma-Aldrich) 50 U/ml for 1 hour (37°C 5% CO₂), followed by a washing step with 15ml
130 RPMI + human serum (HS) 5%. Afterwards all available cells were equally divided to be stim-
131 ulated for 24 hours (37°C 5% CO₂) in 200µl RPMI + HS 5% in 96-well U-bottom plates with
132 mentioned peptide MegaPools (1µg/ml/peptide), PHA-L (Invitrogen) (1µg/ml) as positive con-
133 trol and an equimolar amount of DMSO to serve as negative control. After 24h of stimulation
134 cell culture supernatant was carefully removed and stored at -20°C for later multiplex cytokine
135 analysis. Incubation was stopped by washing cells in PBS. Expression of activation-induced
136 markers (CD69 and OX40) in response to specific peptide stimulation, as well as their memory
137 phenotype were measured by flow cytometry (flow cytometry antibodies are listed in Supple-
138 mentary Table 1).

139 Flow cytometry

140 After thawing, samples for ex-vivo immune phenotyping were washed twice with PBS, equally
141 split into two aliquots, and analyzed with two optimized panels for investigating T cell, B cell
142 and innate immune cell phenotypes, established previously and slightly adapted ¹⁸.

143 The staining procedure for ex-vivo immune phenotyping as well as for PBMC after peptide
144 stimulation was as follows: Cells were stained with Near-IR Dead Cell Stain Kit (Invitrogen)
145 incubated for 15 minutes in the dark at room temperature (RT) and subsequently stained with
146 an antibody cocktail (Supplementary Table 1, Supplementary Figure 1) for 20 minutes at RT.
147 Following washing with PBS, cells were fixed in 1% PFA (Morphisto) for one hour at 4°C,
148 which was removed by PBS wash. Cells were kept at 4°C until acquisition.

149 Comparability of fluorescence intensities was regularly tested with Rainbow Calibration Parti-
150 cles (BD Sphero). For compensation, Anti-Mouse or Anti-Rat Ig, κ/Negative Control Compens-
151 ation Particles Set (BD Biosciences) was used for antibodies, and ArC™ Amine Reactive

152 Compensation Beads (Invitrogen) were used for the Dead Cell Stain Kit. Representative gating
153 strategies are shown in Supplementary Figure 1.

154 Antibody concentrations to achieve optimal separation of targeted populations were evaluated
155 by titration in preliminary experiments using anonymous buffy coats, obtained at the Depart-
156 ment of Transfusion Medicine at the University Medical Center Hamburg-Eppendorf from
157 adult blood donors, who provided their written informed consent.

158 All flow cytometry measurements were performed with a BD FACSymphony A3 flow cytom-
159 eter in the Cytometry and Cell Sorting Core Unit at University Medical Center Hamburg-Ep-
160 pendorf.

161 Multiplex detection of cytokines

162 Detection of cytokines in the cell culture supernatant of stimulated cells was performed using
163 LEGENDplex™ Human CD8/NK Panel (13-plex, BioLegend) suitable for detection of IL-2,
164 IL-4, IL-10, IL-6, IL-17A, TNF- α , sFas, sFasL, IFN- γ , Granzyme A, Granzyme B, Perforin,
165 Granulysin, according to the manufacturer's instructions. Briefly, freshly prepared provided
166 cytokine standard or thawed cell culture supernatant was mixed with cytokine-specific beads,
167 incubated for 2 hours and washed. After sequential incubation of bead-bound cytokines with
168 biotin-labeled cytokine detection antibodies and streptavidin PE antibodies, non-binding anti-
169 bodies were washed off and PE-labeled bead-bound cytokines were subsequently analyzed by
170 flow cytometry. Quantification of cytokines was carried out using the standard. The data was
171 analyzed using the online LEGENDplex™ Data Analysis Software of the manufacturer. The
172 assay was performed in duplicates and mean values of each sample were used for further anal-
173 ysis.

174 Data Analysis and Statistics

175 Data analysis, graphs and statistics were prepared with FlowJo version 10, and R 4.0.5 (pack-
176 ages: tidyverse, rstatix, splines, emmeans, kableExtra, magrittr, heatmaply). Paired sample
177 analyses were performed by paired t-test. The stimulation index and fold increases showed
178 highly skewed distributions and were therefore log-transformed for further analysis. An un-
179 paired t-test was used for comparing two groups. Categorical variables were compared using
180 Fisher's exact test. Comparisons between three groups were done with one-way ANOVA and
181 post hoc pairwise t-tests, if the ANOVA-F test was significant, thus following the closed test
182 principle, no adjustment for multiple testing was necessary for pairwise comparisons. The as-
183 sociation between age and the stimulation index was explored using a non-parametric spline
184 regression with age and serology group and sex as independent variables. An interaction be-
185 tween spline age and serology group was initially included in the model, but it was removed
186 from the final model, if it did not significantly increase the model fit. A p-value < 0.05 was
187 considered as statistically significant in all analyses. As this study had an exploratory nature,
188 we refrained from adjusting for multiple testing.

189 For analysis of flow cytometry experiments, samples with less than 5000 acquired alive CD3+
190 cells (using the DMSO control as reference for peptide stimulations) were excluded from fur-
191 ther analysis.

192 Analysis of AIM+ cells was conducted as described previously^{8,13,14}, by calculating of a stim-
193 ulation index by dividing the frequency of OX40+CD69+ cells within CD4+ cells after peptide
194 stimulation with the frequency of the same cell subset in the negative control (DMSO). In case
195 no OX40+CD69+ cells were detected with DMSO, the lowest detected frequency for DMSO
196 in the given experimental group was used.

197

198 **Results**

199 Study cohort characteristics

200 The study cohort consisted of 126 participants: 51 seropositive children as determined by pos-
 201 itivity in all of three separate serological tests covering the viral Spike and Nucleocapsid, 24
 202 seronegative siblings living in a shared household with an infected individual and 51 age- and
 203 gender-matched unexposed controls. There were no significant differences in the age- and gen-
 204 der distribution of these groups (Table 1). For children whose families were able to give a de-
 205 tailed account of past infection (68 of 75 seropositive children and seronegative siblings), 55%
 206 of seropositives and 43% of seronegative siblings reported symptoms consistent with COVID-
 207 19. Most families with several symptomatic children could no longer recall the exact date of
 208 symptom onset (DSO) for each individual child. However, for 26 out of 35 symptomatic chil-
 209 dren, families were able to recall DSO of the first symptomatic child in the household which
 210 we applied as an approximation to all siblings. The mean time since DSO at the time of sam-
 211 pling was similar within the two groups: 84 days (range 51 – 115 days) for seropositives and
 212 83.4 days (range 62 – 103 days) for seronegative siblings.
 213 SARS-CoV-2 seropositive study participants were all convalescent of an ancestral variant,
 214 closely related to the original Wuhan-Hu-1 strain, since recruiting took place before the occur-
 215 rence of the first SARS-CoV-2 variants of concern.

	Seropositives (n=51)	Seroneg. siblings (n=24)	Unexp. controls (n=51)	p	Test
Age (years, mean ± range)	10.63 (0 - 17)	8.79 (1 - 16)	10.78 (1 - 17)	0.170	ANOVA
Sex (female)	21 (41%)	12 (50%)	27 (53%)	0.523	Fisher's exact
HCoV serology (positive)	25 (49%)	8 (33%)	18 (35%)	0.291	Fisher's exact
	Seropositive (n=47)	Seronegative (n=21)			
Symptoms (yes)	26 (55%)	9 (43%)		0.433	Fisher's exact
	Seropositive (n=21)	Seronegative (n=5)			
Days PSO (mean ± range)	84 (51 - 115)	83.4 (62 - 103)		0.907	t-test

216
 217 **Table 1** Table showing basic characteristics of the cohort. Number of participants (n) per each analysis and subgroup is indi-
 218 cated as data was available. Groups according to SARS-CoV-2 serology: seropositive, seronegative (exposed) siblings, unex-
 219 posed controls. The last two columns describe the statistical analyses per row, the p values were calculated with the statistical
 220 test as indicated in the last column. HCoV: human “common cold” coronaviruses 229E, NL63, OC43, HKU1. PSO: days
 221 post-symptom onset of the first symptomatic child in the family.

222 Antigen-specific CD4⁺ T cells after infection with ancestral SARS-CoV-2 variant

223 PBMC from all donors were stimulated with peptide MegaPools derived from the first de-
224 scribed original SARS-CoV-2 strain (Wuhan-Hu-1) spanning the entire Spike glycoprotein
225 (Spike-OS_MP) and predicted epitopes from the remaining proteome (R_MP). CD4⁺ T cell
226 response was measured based on the expression of AIM markers (OX40 and CD69) and com-
227 pared to a negative control consisting of the peptide mix solvent DMSO at the same concentra-
228 tion as in the peptide mix (Figure 1 A and Supplementary Figure 1 A). When compared to the
229 carrier control (DMSO), stimulation with R_MP led to an increase in the expression of AIM
230 markers in all groups. Increased expression of AIM markers after Spike-OS_MP stimulation
231 was detectable in the seropositive and unexposed control, but not in the seronegative group
232 (Figure 1 B + C). This reflects a combination of antigen-specific CD4⁺ T cell activation to-
233 gether with an additional unspecific immune activation by peptide stimulation itself over
234 DMSO.

235 To account for this unspecific immune activation and to be able to compare between groups,
236 we used the stimulation index (SI), calculated as previously reported ^{8,13,14} as individual MP
237 response divided by DMSO response. SI in the seropositive group was increased over unex-
238 posed controls for R_MP as well as Spike-OS_MP stimulation. Additionally, on Spike-OS_MP
239 stimulation SI was increased in seropositives over seronegative siblings (Figure 1 D + E).

240 By applying a SI threshold of > 3 to define responders ^{8,13,14}, 61 % (31 of 51) of seropositive
241 children showed a specific CD4⁺ T cell response to either Spike-OS_MP or R_MP stimulation,
242 with 55 % (28 of 51) being responsive to Spike-OS_MP and 33 % (17 of 51) to R_MP. This
243 provides further evidence for the generation of antigen-specific T cells after SARS-CoV-2 in-
244 fection in children and additionally underscores the dominant immune response elicited by the
245 SARS-CoV-2 Spike protein.

246 Additionally, reactive T cells were detected in 8 % (2 of 24 Spike-OS_MP) and 13 % (3 of 23
247 R-MP) of seronegative siblings, as well as in 14 % (7 of 51 Spike-OS_MP) and 12 % (6 of 51
248 R_MP) of unexposed controls.

249 Without detectable differences in T cell response between seronegative siblings and unexposed
250 controls, our data indicate that the intensity of exposure to SARS-CoV-2 in household mem-
251 bers, which did not lead to a humoral immune response (seronegative siblings) was generally
252 also not sufficient to induce a systemic CD4⁺ T cell response.

253 Naive versus memory phenotype of AIM⁺ CD4⁺ T cells was determined using CD27 and
254 CD45RA expression (Supplementary Figure 1 A). This revealed that SARS-CoV-2 specific
255 AIM⁺ CD4⁺ T cells predominantly exhibited a central memory phenotype. The proportion of
256 naive cells within the AIM⁺ fraction was, however, higher in younger children paralleling the
257 higher naive fraction in total CD4⁺ cells (Spike – OS_MP in Figure 1 F + G, R_MP and Spike
258 – BV_MP in Supplementary Figure 2).

259 Cross-reactivity to SARS-CoV-2 beta variant after infection with the ancestral variant

260 Occurrence of new SARS-CoV-2 variants of concern, characterized by higher transmissibility
261 and a certain immune escape has changed the pandemic's dynamic several times, reviewed in
262 ¹⁹. It is therefore of great interest whether T cell responses to earlier SARS-CoV-2 infections or
263 the current vaccinations approved in children, which are based on the original Wuhan-Hu-1
264 strain by either containing inactivated virus^{20,21} or the Spike protein sequence^{22,23}, lead to gen-
265 eration of cross-reactive CD4⁺ T cells against new SARS-CoV-2 variants.

266 We evaluated the T cell response towards the beta variant, a WHO variant of concern due to its
267 capability to escape humoral immunity ²⁴, in archived pediatric samples after infection with an
268 ancestral SARS-CoV-2 variant. PBMC were stimulated with a peptide MegaPool of overlap-
269 ping peptides spanning the entire Spike glycoprotein of the beta variant (Spike-BV_MP). This
270 resulted in a significant increase of CD4⁺ AIM markers in the seropositive cohort (Figure 2 A).

271 45 % of seropositives (23 of 51), 12 % of unexposed controls (6 of 51) and 21 % of seronegative
272 siblings (5 of 24) could be identified as responders ($SI > 3$). SI was significantly higher in sero-
273 positive individuals when compared to unexposed controls and seronegative siblings (Figure 2
274 B). Our results suggest that prior infection with an ancestral SARS-CoV-2 variant is associated
275 with the generation of T cells showing reactivity against the immune escaping SARS-CoV-2
276 beta variant in a relevant proportion of children.

277 Lower antigen-specific T cell detection rate in very young children

278 We analyzed the effect of age on SARS-CoV-2 specific CD4⁺ T cell responses (Figure 2
279 C,D,E), by applying a non-parametric spline model to fit the data on T cell responses as meas-
280 ured by SI plotted by age in years. This model predicts an increase in antigen specific CD4⁺ T
281 cell response with age, until a plateau is reached between ten and fifteen years. Also, we de-
282 tected an impaired capacity to mount specific T cell responses ($SI > 3$) in preschool children
283 using all tested SARS-CoV-2-derived peptide pools. At the same time, we did not detect an
284 overall reduced capacity of CD4⁺ T cells in younger children to express AIMs upon activation
285 in the positive control (PHA, Supplementary Figure 4).

286 Influence of prior HCoV infections

287 To evaluate the possible influence of T cell cross reactivity elicited by prior infections with
288 common cold Coronavirus (HCoV), we assessed the serostatus of HCoV strains 229E, NL63,
289 OC43 and HKU1 in all study participants. 40 % of the participants in the study were identified
290 as seropositive for at least one of the tested strains. When comparing T cell response quantified
291 as SI for stimulation with R_MP, Spike – OS_MP and Spike – BV_MP between participants
292 with positive and negative HCoV serology, no difference could be seen regardless of SARS-
293 CoV-2 serostatus (Spike – OS_MP Figure 2 F blue and grey, R_MP and Spike – BV_MP in
294 Supplementary Figure 3). Some, but not all unexposed controls and seronegative siblings with

295 SI > 3 in any of the peptide pools had a positive HCoV serology. This indicates that the identi-
296 fied SARS-CoV-2 reactive T cells in seronegative siblings and unexposed controls cannot be
297 explained only by cross reactive T cell memory from prior HCoV infections.

298 Cytokine profile of SARS-CoV-2-reactive T cells

299 To further characterize the T cell response, thirteen different cytokines were measured in cul-
300 ture supernatants after exposure of PBMC to SARS-CoV-2 peptide MegaPools. We could de-
301 tect increased cytokine levels for nearly all of the quantified cytokines after peptide stimulation
302 when compared to DMSO negative control (data not shown). To control for unspecific or by-
303 stander immune activation and to be able to attribute cytokine secretion to a specific T cell
304 response, we calculated fold increases in cytokine concentration after peptide stimulation over
305 cytokine concentration in corresponding DMSO negative controls analogous to the stimulation
306 index for T cell response. These were compared between seropositive children with a clear T
307 cell response (SI > 3 as quantified using activation induced markers) and unexposed controls
308 and seropositive children both without a clear T cell response (SI < 3).

309 The analysis revealed levels of IFN- γ and Granzyme B, both associated with viral defense, were
310 consistently higher in seropositive T cell responders after Spike-OS_MP, R_MP and Spike-
311 BV_MP stimulation compared seropositives and unexposed controls both without a T cell re-
312 sponse (Figure 3 A – F). Since PBMC were stimulated in bulk, the elevated IFN- γ and espe-
313 cially Granzyme B levels could indicate concomitant CD8⁺ activation.

314 In seropositive T cell responders, R_MP stimulation led to an increased secretion of IL-2 (Fig-
315 ure 3 G) and Granzyme A (Figure 3 H). Interestingly, the beta-variant-based Spike-BV_MP
316 was the only peptide pool eliciting the secretion of anti-inflammatory IL-10 in association with
317 a CD4⁺ T cell response (Figure 3 I, IL-2 and Granzyme A response not shown for Spike-
318 OS_MP and Spike-BV_MP. IL-10 not shown for Spike-OS_MP and R_MP).

319 No long-term alterations of the immune phenotype in convalescent pediatric patients

320 Respiratory infections are known to elicit long-term changes in the phenotype of innate and
321 adaptive immune cell populations^{25,26}. Therefore, we performed a broad immunologic pheno-
322 typing of study participants in parallel PBMC samples using two flow cytometry panels for a
323 detailed T cell profiling and quantification of main immune cell subsets, respectively (Supple-
324 mentary Figure 1 B and C). We found that the relative abundance of T-, B- and innate cell
325 subsets was similar in seropositive children, seronegative siblings and unexposed controls (Fig-
326 ure 4 A and B). Thus, in this pediatric cohort, no long-term immune phenotypic changes after
327 SARS-CoV-2 infection or exposure could be demonstrated.

328

329 **Discussion**

330 Antigen specific CD4+ T cells play a central role in the immune response to a viral infection,
331 as they may reduce disease severity after re-infection by a more rapid clearance of the virus and
332 better overall disease control, as reviewed in²⁷. The presence of antigen specific T cells after
333 SARS-CoV-2 infection in adult cohorts has been widely demonstrated^{7-10,14,28-30}. Here, we
334 analyzed the T cell response in a large cohort of SARS-CoV-2 convalescent children, their
335 seronegative siblings as well as unexposed controls. We provided further evidence that a high
336 proportion of children who seroconverted to SARS-CoV-2 were able to mount specific CD4+
337 T cell responses, that were still detectable up to over 100 days after infection. In contrast to
338 adult cohorts³¹ we could identify specific T cell responses in only a minority of SARS-CoV-2
339 exposed but not seroconverted children (seronegative siblings). In our pediatric cohort we
340 showed a T cell response attributable to a prior SARS-CoV-2 infection in 61% of seropositive
341 children, which is less than the reported response rates of 77 – 100% of acutely ill^{7,10,14} and 81
342 – 100% of convalescent adult patients^{8,10,12,29,30}. These findings are in line with previous studies
343 investigating systemic T cell responses in children after respiratory infections like SARS-CoV-
344 2^{15,16} or Influenza³².

345 Until now data on pediatric T cell response after SARS-CoV-2 infection is scarce with cohort
346 sizes not allowing for analysis over different age groups ^{15,16}. Importantly, we showed an in-
347 crease in SARS-CoV-2-specific CD4⁺ T cell responses by age within this pediatric cohort.
348 Reduced capacity to mount specific T cell responses was particularly seen in preschool children.
349 A comparable age-effect showing lower T cell responses after SARS-CoV-2-infection in chil-
350 dren than adults has previously been demonstrated ¹⁶. Such age related differences have been
351 reported, especially in infants, regarding the interplay between innate and adaptive immunity
352 and the development of memory T cell responses including a lower inflammatory reaction upon
353 pathogen challenge and vaccination ^{33,34}.

354 We provided functional data on the phenotype of the pediatric CD4⁺ T cell response to SARS-
355 CoV-2 in children showing a strong antiviral response and provide indirect evidence for a cy-
356 totoxic CD8⁺ response involving Granzyme B production. Predominant CD4⁺ T cell response
357 in convalescent children is likely of Th1 bias (IFN- γ).

358 While a large proportion of seroconverted children appeared to mount strong T cell responses,
359 long-term changes in the immunological phenotype of innate and adaptive cell populations
360 seem not to affect children after SARS-CoV-2 infection. Notably, children in this cohort were
361 typically sampled about three months after COVID-19, with only a minority having exhibited
362 symptoms of infection in the first place. These characteristics may explain the quick normali-
363 zation of any immunological changes post infection in this cohort. Conversely, in cohorts with
364 a larger proportion of symptomatic or seriously ill children, also CD4⁺ T cell reactivity could
365 be higher.

366 Cross-reactive T cells have the potential to reduce disease severity of infections with new viral
367 strains, reviewed in ^{35,36}. The presence of SARS-CoV-2 reactive CD4⁺ T cells in unexposed
368 individuals could be shown ^{7,12,14,29,30} and cross reactivity of CD4⁺ T cells to epitopes of HCoV
369 and SARS-CoV-2 was demonstrated ³⁷. We analyzed the influence of prior HCoV infections
370 on pediatric SARS-CoV-2 T cell response. In our cohort, we could not detect a difference in

371 the CD4⁺ T cell response (quantified by SI) upon SARS-CoV-2-derived peptide stimulation
372 between HCoV seropositive and seronegative individuals. Also, SARS-CoV-2-reactive T cells
373 in unexposed controls were only present in a fraction of cases associated with a positive HCoV
374 serology. We observed a seropositivity for HCoV in 49% of SARS-CoV-2 seropositive and
375 33% of SARS-CoV-2 exposed participants while no severe disease courses were reported in
376 our cohort. It would follow, that the comparatively mild course of COVID-19 in children is not
377 mainly or exclusively explained by their more frequent or recent exposures to related human
378 coronaviruses. More likely, reduced disease severity and lower T cell responses in children are
379 offset by an enhanced capability of innate, tissue resident immune responses in the upper air-
380 ways resulting in early SARS-CoV-2 control in this age group ³⁸.

381 Importantly, by making use of our relatively large cohort of archived pediatric samples, we
382 demonstrated for the first time to our knowledge a cross reactivity of T cells after infection with
383 an ancestral SARS-CoV-2 variant to an immune escaping SARS-CoV-2 variant of concern
384 (B.1.351-beta variant) in a pediatric population. This adds on to previous findings, describing
385 cross reactive T cells to B.1.351, B.1.1.7 (alpha-variant), B.1.617.2 (delta-variant) and
386 B.1.1.529 (omicron-variant) in adult cohorts after SARS-CoV-2 infection or vaccination ^{30,39-}
387 ⁴¹. T cell response to the beta variant may serve as a raw model for immune escaping variants,
388 as immune escape is mainly attributed to its mutation on position E484 within the spike domain,
389 which is associated with reduced affinity of neutralizing antibodies ⁴² and mutations on this site
390 are also found in SARS-CoV-2 strains B.1.617.2 (gamma), B.1.621 (mu) or B.1.1.529 (omi-
391 cron) ⁴³.

392 Our data provide important evidence for a certain cross reactivity of the pediatric CD4⁺ T cell
393 response after infection with an ancestral SARS-CoV-2 variant to mutations in the Spike do-
394 main. Current SARS-CoV-2 vaccines approved for use in children, consisting of inactivated
395 virus^{20,21} or the genetic information of the Spike protein ^{22,23}, are based on the original SARS-
396 CoV-2 Wuhan-Hu-1 strain. Based on our data generated by stimulation of archived samples

397 from the first wave with peptide MegaPools derived from the later evolved beta variant, we can
398 hypothesize that these vaccines should still elicit adequate T cell responses to emerging immune
399 escaping variants in children. CD4⁺ T cell responses in preschool children were reduced, which
400 may be offset by antibody responses⁴⁴ or increased innate responses³⁸. Nonetheless, the role
401 of a lower CD4⁺ memory T cell response in the youngest should be considered when planning
402 vaccination strategies and if emerging viral variants cause a rise in pediatric disease burden.
403 Notably, first data from the United States indicate an increased hospitalization rate especially
404 in this age group facing the current omicron variant⁵.

405 Our study had several limitations. As children were recruited weeks or months after infection,
406 no PCR based confirmation from the acute phase of infection was available. As previous infec-
407 tion was defined through seropositivity alone, a combined positivity in three independent sero-
408 logical tests was required and this approach should minimize the possibility of false positives.
409 A further limitation based on the retrospective study design is that a detailed history from the
410 time of infection as well as the exact time of infection could only be collected for a fraction of
411 participants. Because of a reluctance in small children and their caregivers, as well as the tech-
412 nical difficulty regarding blood draws, younger age groups were relatively underrepresented.
413 Also, CD8⁺ T cell responses were not investigated - these could provide important insights into
414 cellular anti-SARS-CoV-2 immunity and should be the focus of further studies.

415

416 **Conclusion**

417 Here we showed that pediatric CD4⁺ T cell responses after infection with an ancestral SARS-
418 CoV-2 variant are age dependent, with reduced capability of the youngest to mount specific
419 responses. Antigen specific T cells persist over three months after infection and are cross reac-
420 tive with the SARS-CoV-2 variant of concern B.1.351-beta variant. We detected a strong anti-
421 viral cytokine response in association with SARS-CoV-2-specific T cell activation. Our

422 findings have relevance when planning rational vaccination of children as well as social dis-
423 tancing measures involving the pediatric population in case of emerging SARS-CoV-2 variants.

424

425 **Acknowledgements:**

426 The C19.CHILD Hamburg Study received funding from the Senate Chancellery of the Free and
427 Hanseatic City of Hamburg. The following foundations and organizations have provided finan-
428 cial support: Carlsen Verlag, Dr. Melitta Berkemann Stiftung, Fördergemeinschaft Kinder-
429 krebs-Zentrum Hamburg e.V., Freunde der Kinderklinik des UK Eppendorf e.V., HSV Fussball
430 AG, Joachim-Herz-Stiftung, Michael Otto Stiftung, Michael Stich Stiftung, Nutricia, Stiftung
431 KinderHerz, EAGLES Charity Golf Club e.V., DAMP Stiftung, Kroschke Stiftung, ZEIT-Stif-
432 tung.

433

434 **Author Contributions:**

435 KP, SWG and GAD conceived the study. KP, FS and GAD performed T cell stimulation assays,
436 cytokine analysis and immune phenotyping. ML supervised serology testing. KP, FS, DW, MB,
437 AS, ET, JSzW, ML, SWG and GAD contributed to the experiment design and methodology.
438 JO, TSM, ACM, SWG, GAD were responsible for study supervision and funding. KP, MW,
439 KH, AK, DEZ, LH, MKD, JO, TSM, ACM, GAD coordinated the study cohort and acquired
440 patient samples. Sample preparation was supervised by KP, FS and GAD. KP, GAD, LG, ET,
441 EV, and AZ performed data- and statistical analysis and prepared graphs. All authors provided
442 conceptual input, KP, FS and GAD wrote the manuscript, which was critically revised by all
443 authors.

444

445 **Conflict of Interest:**

446 All authors declare no conflict of interest.

447

448 **References**

- 449 1 Zhu N, Zhang D, Wang W, Li X, Yang B, Song J *et al.* A Novel Coronavirus from Patients
450 with Pneumonia in China, 2019. *N Engl J Med* 2020; **382**: 727–733.
- 451 2 Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and
452 Engineering (CSSE). <https://coronavirus.jhu.edu/map.html> (accessed 22 Jan2022).
- 453 3 Preston LE, Chevinsky JR, Kompaniyets L, Lavery AM, Kimball A, Boehmer TK *et al.*
454 Characteristics and Disease Severity of US Children and Adolescents Diagnosed with
455 COVID-19. *JAMA Netw Open* 2021; **4**: 8–11.
- 456 4 Dong Y, Dong Y, Mo X, Hu Y, Qi X, Jiang F *et al.* Epidemiology of COVID-19 among
457 children in China. *Pediatrics* 2020; **145**. doi:10.1542/peds.2020-0702.
- 458 5 CDC Covid-Net. A weekly summary of U.S. COVID-19 hospitalization data; Laboratory-
459 Confirmed COVID-19-Associated Hospitalizations.
460 https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html (accessed 22 Jan2022).
- 461 6 Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A *et al.* Comparative
462 analysis of activation induced marker (AIM) assays for sensitive identification of
463 antigen-specific CD4 T cells. *PLoS One* 2017; **12**: 1–22.
- 464 7 Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F *et al.* SARS-CoV-2-reactive
465 T cells in healthy donors and patients with COVID-19. *Nature* 2020.
466 doi:10.1038/s41586-020-2598-9.
- 467 8 Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR *et al.* Targets of
468 T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
469 Unexposed Individuals. *Cell* 2020; **181**: 1489-1501.e15.
- 470 9 Jung JH, Rha MS, Sa M, Choi HK, Jeon JH, Seok H *et al.* SARS-CoV-2-specific T cell


- 471 memory is sustained in COVID-19 convalescent patients for 10 months with successful
472 development of stem cell-like memory T cells. *Nat Commun* 2021; **12**: 1–12.
- 473 10 Rydzynski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D *et al.*
474 Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and
475 Associations with Age and Disease Severity. *Cell* 2020; **183**: 996-1012.e19.
- 476 11 Schub D, Klemis V, Schneitler S, Mihm J, Lepper PM, Wilkens H *et al.* High levels of
477 SARS-CoV-2–specific T cells with restricted functionality in severe courses of COVID-
478 19. *JCI Insight* 2020; **5**. doi:10.1172/jci.insight.142167.
- 479 12 Steiner S, Sotzny F, Bauer S, Na IK, Schmueck-Henneresse M, Corman VM *et al.* HCoV-
480 and SARS-CoV-2 Cross-Reactive T Cells in COVID Patients. *Front Immunol* 2020; **11**: 1–
481 10.
- 482 13 Thieme CJ, Anft M, Paniskaki K, Blazquez-Navarro A, Doevelaar A, Seibert FS *et al.*
483 Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2
484 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients. *Cell Reports*
485 *Med* 2020; **1**. doi:10.1016/j.xcrm.2020.100092.
- 486 14 Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H *et al.*
487 Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute
488 respiratory distress syndrome. *Sci Immunol* 2020; **5**: eabd2071.
- 489 15 Kaaijk P, Olivo Pimentel V, Emmelot ME, Poelen M, Cevirgel A, Schepp RM *et al.*
490 Children and adults with mild COVID-19 symptoms develop memory T cell immunity
491 to SARS-CoV-2. *medRxiv* 2021; : 2021.09.10.21263333.
- 492 16 Cohen CA, Li APY, Hachim A, Hui DSC, Kwan MYW, Tsang OTY *et al.* SARS-CoV-2
493 specific T cell responses are lower in children and increase with age and time after
494 infection. *Nat Commun* 2021; **12**: 1–14.

- 495 17 Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence
496 Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune
497 Responses to SARS-CoV-2. *Cell Host Microbe* 2020; **27**: 671-680.e2.
- 498 18 Sibbertsen F, Glau L, Paul K, Mir TS, Gersting SW, Tolosa E *et al.* Phenotypic analysis of
499 the pediatric immune response to SARS-CoV-2 by flow cytometry. *Cytometry A* 2021.
500 doi:10.1002/cyto.a.24528.
- 501 19 Bertoletti A, Le Bert N, Qui M, Tan AT. SARS-CoV-2-specific T cells in infection and
502 vaccination. *Cell Mol Immunol* 2021. doi:10.1038/s41423-021-00743-3.
- 503 20 Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF *et al.* Safety and immunogenicity of
504 an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-
505 controlled, phase 1/2 trial. *Lancet Infect Dis* 2021; **21**: 39–51.
- 506 21 Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W *et al.* Development of an
507 Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-
508 2. *Cell* 2020; **182**: 713-721.e9.
- 509 22 Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S *et al.* Phase I/II
510 study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature* 2020; **586**: 589–593.
- 511 23 Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA *et al.*
512 SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
513 *Nature* 2020; **586**: 567–571.
- 514 24 Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM *et al.* SARS-
515 CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol* 2021; **19**:
516 409–424.
- 517 25 Rouers A, Chng MHY, Lee B, Rajapakse MP, Kaur K, Toh YX *et al.* Immune cell
518 phenotypes associated with disease severity and long-term neutralizing antibody

- 519 titers after natural dengue virus infection. *Cell Reports Med* 2021; **2**.
- 520 doi:10.1016/j.xcrm.2021.100278.
- 521 26 Weng K, Zhang J, Mei X, Wu A, Zhang B, Cai M *et al*. Lower number of plasmacytoid
522 dendritic cells in peripheral blood of children with bronchiolitis following respiratory
523 syncytial virus infection. *Influenza Other Respi Viruses* 2014; **8**: 469–473.
- 524 27 Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4 + T cells in immunity to
525 viruses. *Nat Rev Immunol* 2012; **12**: 136–148.
- 526 28 Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE *et al*. Immunological memory to
527 SARS-CoV-2 assessed for up to 8 months after infection. *Science (80-)* 2021; **371**.
528 doi:10.1126/science.abf4063.
- 529 29 Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A *et al*. SARS-CoV-2-
530 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
531 *Nature* 2020; **584**: 457–462.
- 532 30 Jordan SC, Shin BH, Gadsden TAM, Chu M, Petrosyan A, Le CN *et al*. T cell immune
533 responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and
534 vaccinated individuals. *Cell Mol Immunol* 2021; **18**: 2554–2556.
- 535 31 Wang Z, Yang X, Zhong J, Zhou Y, Tang Z, Zhou H *et al*. Exposure to SARS-CoV-2
536 generates T-cell memory in the absence of a detectable viral infection. *Nat Commun*
537 2021; **12**: 6–13.
- 538 32 Shannon I, White CL, Murphy A, Qiu X, Treanor JJ, Nayak JL. Differences in the
539 influenza-specific CD4 T cell immunodominance hierarchy and functional potential
540 between children and young adults. *Sci. Rep.* 2019; **9**. doi:10.1038/s41598-018-37167-
541 5.
- 542 33 Prabhudas M, Adkins B, Gans H, King C, Levy O, Ramilo O *et al*. Challenges in infant

- 543 immunity: Implications for responses to infection and vaccines. *Nat Immunol* 2011;
544 **12**: 189–194.
- 545 34 Pichichero ME. Challenges in vaccination of neonates, infants and young children.
546 *Vaccine* 2014; **32**: 3886–3894.
- 547 35 Selin LK, Wlodarczyk MF, Kraft AR, Nie S, Kenney LL, Puzone R *et al.* Heterologous
548 immunity: Immunopathology, autoimmunity and protection during viral infections.
549 *Autoimmunity* 2011; **44**: 328–347.
- 550 36 Agrawal B. Heterologous Immunity: Role in Natural and Vaccine-Induced Resistance to
551 Infections. *Front Immunol* 2019; **10**: 1–11.
- 552 37 Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM *et al.* Selective and cross-
553 reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science (80-)* 2020; **370**:
554 89–94.
- 555 38 Loske J, Röhm J, Lukassen S, Stricker S, Magalhães VG, Liebig J *et al.* Pre-activated
556 antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in
557 children. *Nat Biotechnol* 2021. doi:10.1038/s41587-021-01037-9.
- 558 39 Neidleman J, Luo X, McGregor M, Xie G, Murray V, Greene WC *et al.* mRNA vaccine-
559 induced SARS-CoV-2-specific T cells recognize B.1.1.7 and B.1.351 variants but differ in
560 longevity and homing properties depending on prior infection status. *bioRxiv Prepr*
561 *Serv Biol* 2021. doi:10.1101/2021.05.12.443888.
- 562 40 Keeton R, Tincho MB, Ngomti A, Baguma R, Suzuki A, Khan K *et al.* SARS-CoV-2 spike T
563 cell responses induced upon vaccination or infection remain robust against Omicron.
564 2021; : 1–20.
- 565 41 Choi SJ, Kim D, Park S. CORRESPONDENCE T cell epitopes in SARS-CoV-2 proteins are
566 substantially conserved in the Omicron variant. 2022; : 1–2.

- 567 42 Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY *et al.*
568 Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain
569 that affect recognition by polyclonal human plasma antibodies. *Cell Host Microbe*
570 2021; **29**: 463-476.e6.
- 571 43 Scripps Research. outbreak.info - a standardized, open-source database of COVID-19
572 resources and epidemiology data. <https://outbreak.info/situation-reports> (accessed
573 22 Jan2022).
- 574 44 Roarty C, Tonry C, McFetridge L, Mitchell H, Watson C, Waterfield T *et al.* Kinetics and
575 seroprevalence of SARS-CoV-2 antibodies in children. *Lancet Infect. Dis.* 2020.
576 doi:10.1016/S1473-3099(20)30884-7.
577



medRxiv preprint doi: <https://doi.org/10.1101/2022.01.27.22269976>; this version posted January 28, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.




Figure 1

A: Flow cytometry results of a representative SARS-CoV-2 seropositive study participant, gated on alive CD3+ CD4+ lymphocytes. PBMC were equally divided and stimulated over 24h with either DMSO (negative control), PHA-L (positive control) or SARS-CoV-2 derived peptide MegaPools covering the spike glycoprotein of the original strain Wuhan-Hu-1 (Spike-OS_MP), beta variant (Spike-BV_MP) or the remaining original strain's proteome (R_MP). CD4 AIM+ T cells were identified by their CD69 and OX40 expression. CD4 AIM+ gate was set equal for all samples of all participants after comparability of fluorescence intensities was assured by rainbow bead calibration.

B + C: Frequency of AIM+ cells, determined by CD69 and OX40 expression, after stimulation with R_MP and Spike -OS_MP in comparison to AIM+ frequency after DMSO exposure. Study groups were determined by their SARS-CoV-2 serostatus and SARS-CoV-2 exposure. Paired t-tests were used to determine P values.

D+ E: Comparison of T cell response towards peptide stimulation between study groups. T cell response was quantified by using a Stimulation Index (SI) which was calculated by dividing the freq. of AIM+ cells after peptide stimulation by the freq. of AIM+ cells of the DMSO negative control. A SI > 3 (dashed line) was defined as response. Statistical comparisons were carried out by one way ANOVA and post hoc pairwise t-tests.

F + G: Memory phenotype of total CD4+ and AIM+CD4+ T cells after peptide stimulation with Spike - OS_MP. Mean values of all study participants irrespective of SARS-CoV-2 serostatus are displayed

*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns - not significant




Figure 2

A: Frequency of AIM+ cells after stimulating PBMC with Spike – BV_MP and DMSO negative control. Paired t – tests were used to quantify P – values.

B: Comparison of T cell response, quantified by stimulation index, to Spike – BV_MP peptide pool between study groups. Statistical analysis was performed with one way ANOVA followed by pairwise t – tests. $SI > 3$ (dashed line) was defined as response.

C + D + E T cell responses upon peptide stimulation as quantified by stimulation index are displayed according to the participants’ age. Each dot represents the T cell response of an individual seropositive study participant. The respective peptide pool is indicated on top of each graph. The effect of age on the magnitude of T cell response, was further analyzed with a non-parametric multivariate regression analysis, by using a spline model (blue lines with light blue areas indicating 95% confidence intervals).

F: T cell responses towards Spike – OS_MP stimulation were compared between participants with different serostatus for “common cold” coronaviruses (HCoV, strains 229E, NL63, OC43 and HKU1). Analyses were conducted within study groups, which were defined by SARS-CoV-2 exposure and serostatus. Unpaired t – test was used to quantify P values.

*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns - not significant




Figure 3

The concentration of 13 cytokines was determined in cell culture supernatants after stimulation with SARS-CoV-2-derived peptide MegaPools. The respective peptide pool, used for stimulation, is indicated on top of each graph. Comparison was conducted between seropositive children with and without a clear T cell response and unexposed controls without a T cell response. T cell response was defined as a stimulation index (SI) > 3 in the AIM assay upon peptide stimulation

A – I: Comparison of IFN-γ, Granzyme B, IL-2, Granzyme A and IL-10 secretion between groups. To adjust for unspecific cytokine secretion, comparison was performed by using the fold increase in cytokine concentration after peptide stimulation over cytokine concentration in DMSO treated samples. One way ANOVA and post hoc pairwise t – tests were used to quantify P values.

*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, not significant – not displayed




Figure 4

Heatmaps showing the relative frequency of **T cell subsets (A)** as frequency of CD3 positive live cells and **B- and innate cell subsets (B)** as frequency of CD45 positive live cells. Further subdivision of subsets is indicated by forward slash “/”, whereby the parent population is indicated in front of the child population. The frequencies have been normalized for each cellular subset to utilize the full color scale, which is indicated to the right of both panels. Each row represents a PBMC sample from a single participant. Samples are grouped according to seroconversion status (right y axis). Furthermore, samples within groups are sorted vertically according to the age of the participant, beginning with the oldest (top) to the youngest (bottom).

MAIT: Mucosa Associated Invariant T cells, Treg: regulatory T cells, Tcm: central memory T cells, Tem: effector memory T cells, Tn: naive T cells, RTE: recent thymic emigrants, Tfh: T follicular helper cells, Th: T helper cells, HLA: human leukocyte antigen, BTLA: B- and T-lymphocyte attenuator, PD-1: programmed death 1, TIGIT: T cell immunoreceptor with Ig and ITIM domains, Tte: terminally differentiated effector T cell, Ttm: transitional memory T cell, pDC: plasmacytoid dendritic cells, NK: natural killer cells, ILC: innate lymphoid cells.

Supplementary Material for the manuscript entitled:

Evaluation of the CD4+ T cell response to SARS-CoV-2 infection and cross reactivity to beta variant in children of all ages


Contents

Supplementary Table 1. Flow cytometry reagent list.....	2
Supplementary Figure 1A. Gating strategy for activation induced markers “Panel AIM”	3
Supplementary Figure 1B. Gating strategy for immune phenotyping, “T cells”	4
Supplementary Figure 1C. Gating strategy for immune phenotyping, “B cells and innate immune cells”	5
Supplementary Figure 2. Memory phenotypes upon peptide stimulation	6
Supplementary Figure 3. T cell response to peptide stimulation compared between different HCoV serostatus within study groups.....	7
Supplementary Figure 4. T cell response to stimulation by PHA-L (positive control) according to experimental groups and age	8

Supplementary Table 1. Flow cytometry reagent list.


ANTIGEN	FLUOROCHROME	CLONE	SUPPLIER	#CAT
BTLA	BV421	MIH26	Biologend	344512
CCR6	APC	G034E3	Biologend	353416
CD117	APC	104D2	Biologend	313206
CD123	PE-Cy7	6H6	Biologend	306010
CD127	BUV 737	HIL-7R- M21	BD	612794
CD134 (OX40)	PE-Cy7	Ber- ACT35	Biologend	350012
CD137	APC	4B4-1	Biologend	309809
CD14	BUV 563	M5E2	BD	741360
CD16	BV605	3G8	Biologend	302039
CD161	BV421	HP-3G10	Biologend	339914
CD19	AF700	SJ25C1	Biologend	363034
CD25	PE	M-A251	Biologend	356104
CD27	BV650	O323	Biologend	302827
CD27	BV421	O323	Biologend	302824
CD28	AF700	CD28.2	Biologend	302920
CD294 (CRTH2)	PE	BM16	Biologend	350106
CD3	BV785	OKT3_	Biologend	317330
CD31	BV605	WM59	Biologend	303122
CD38	PerCp-Cy5.5	HIT2	Biologend	303521
CD4	BUV 395	SK-3	BD	563552
CD4	BV605	SK-3	Biologend	344646
CD45	BUV 395	HI30	BD	563792
CD45RA	BV510	HI100	Biologend	304142
CD56	PE-Dazzle	5.1H11	Biologend	362544
CD69	FITC	FN50	Biologend	310903
CD8	BUV 563	RPA-T8	BD	612914
CD8	AF700	RPA-T8	Biologend	301028
CXCR3	PE-Cy7	G025H7	Biologend	353719
CXCR5	PerCp-Cy5.5	J252D4	Biologend	356910
HLA-DR	FITC	G46-6	BD	555811
IGD	BV510	IA6-2	Biologend	348220
LIVE/DEAD DUMP	APC-Cy7	NA	Life	L10119
PD-1	BV711	EH12.2H7	Biologend	329928
TIGIT	PE-Dazzle	A15153G	Biologend	372716

Supplementary Figure 1A. Gating strategy for activation induced markers “Panel AIM”




Manual gating strategy for the gating of activation induced markers. Names of subpopulations are shown along with frequency within the parent population. The parent population is indicated above the plots or by arrows showing backgating. For stimulation, the different conditions (negative, positive controls or peptide megapools) are indicated above the plots.

Supplementary Figure 1B. Gating strategy for immune phenotyping, “T cells”




Manual gating strategy for T cell subpopulations on a representative sample. Names of subpopulations are shown along with frequency within the parent population. The parent population is indicated above the plots or by arrows showing backgating.

Supplementary Figure 1C. Gating strategy for immune phenotyping, “B cells and innate immune cells”




Manual gating strategy for B cells and innate immune cells on a representative sample. Names of subpopulations are shown along with frequency within the parent population. The parent population is indicated above the plots or by arrows showing backgating.

Supplementary Figure 2. Memory phenotypes upon peptide stimulation




Memory phenotypes of total CD4+ and AIM+CD4+ T cells after peptide stimulation with R_MP (A + B) and Spike -BV_MP (C + D). Mean values of all study participants irrespective of SARS-CoV-2 serostatus are displayed.

Supplementary Figure 3. T cell response to peptide stimulation compared between different HCoV serostatus within study groups



Comparison of T cell response towards R_MP and Spike – BV_MP stimulation between their different serostatus for “common cold” coronaviruses (HCoV). Analyses were conducted within study groups, which were defined by SARS-CoV-2 exposure and serostatus. Unpaired t – test was used to quantify P values. ns - not significant.

Supplementary Figure 4. T cell response to stimulation by PHA-L (positive control) according to experimental groups and age



Panels according to experimental groups as indicated on top. T cell responses in the positive control, phytohemagglutinin (PHA-L) are displayed as quantified by stimulation index according to the participants' age. Dots represent individual T cell responses. The effect of age on the magnitude of T cell response was analyzed with a non-parametric multivariate regression analysis, by using a spline model (blue lines with light blue areas indicating 95% confidence intervals).